| EPB180 | Long-acting cabotegravir+rilpivirine in older adults: pooled Phase 3 Week 96 | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB181 | 'Give it a Shot': best practices from HCPs for administering long-acting cabotegravir+rilpivirine | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB182 | Long-acting cabotegravir+rilpivirine injection site reactions: pooled Week 96 results | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB183 | Week 96 weight and lipid changes from baseline among participants receiving cabotegravir and rilpivirine long-acting or comparator therapy in the ATLAS-2M and FLAIR studies | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB184 | Injection site reaction experience in clinical studies of people using lenacapavir for HIV treatment | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB185 | Preference for long acting injectable (LAI) antiretrovirals for HIV treatment or PrEP in Argentina | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB186 | Early implementation and clinical outcomes of long-acting injectable cabotegravir and rilpivirine in a safety-net HIV clinic | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPLBB05 | Safety and effectiveness outcomes from the Carisel study: phase 3b hybrid-3 implementation study integrating cabotegravir + rilpivirine long-acting into European clinical settings | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| PESUB24 | A study evaluating the safety, tolerability, and pharmacokinetics of a high-concentration (CAB 400mg/ml) cabotegravir long-acting injectable formulation following subcutaneous and intramuscular administration in healthy adult participants | Poster exhibition | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPD469 | Old driver, new insight: the perspective of Spanish-speaking drug users on HIV and overdose prevention | E-poster | Living with HIV and co-infections and/or co-morbidities |